Cipla Results
- All
- News
- Videos
-
Cipla Q3 Profit Dips 2.6% To Rs 729 Crore
Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021
-
Cipla Records Rs 712 Crore Net Profit In September Quarter
The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore
-
Nifty Seen Opening Higher; Axis Bank, Kotak Bank, Cipla In Focus
Foreign institutional investors sold shares worth Rs 2,459 crore on Monday while domestic institutional investors bought shares worth Rs 2,390 crore.
-
Cipla Extends Gains For Second Straight Day On Strong June Quarter Earnings
On Friday, the company had reported a net profit of Rs 577.91 crore in the quarter ended June 30, marking a jump of 20.85 per cent compared to the corresponding period a year ago.
-
Cipla Hits Record High After Strong June Quarter Earnings
Cipla Share Price: By 11:22 am, 6.88 lakh Cipla shares had changed hands on the BSE, as against an average of 3.49 lakh over the past two weeks.
-
Cipla June Quarter Profit Jumps 21%
Cipla's revenue from the pharmaceuticals segment rose 7.73 per cent to Rs 4,266.09 crore.
-
Cipla Profit Rises 6% To Rs 478 Crore In June Quarter
Cipla's revenue from its pharmaceuticals business increased 1.22 per cent to Rs 3,959.93 crore in the quarter ended June 30.
-
Cipla Q2 Net Profit Falls 11%, Misses Street Estimates
The upcoming challenges include capacity balancing in certain categories at plants and sanctions, Cipla said in a post-earnings presentation.
-
Cipla Q2 Profit Soars 19 per Cent To Rs 423 Crore On Higher Domestic Sales
Cipla posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.
-
Cipla Shares Jump Over 7% Post Q2 Results
Drug major Cipla yesterday reported a 34.74 per cent slide in consolidated net profit to Rs 354.34 crore for the second quarter ended September 2016, mainly on account of increase in expenditure.
-
Cipla Slips as CLSA Downgrades Stock
CLSA said that the business transformation could take longer than expected and results could take time to deliver.
-
Sensex Turns Flat After Strong Start; Nifty Holds 6,650
Indian stocks have witnessed low volumes and high volatility over the last 7-8 sessions. The Sensex has shed over 500 points since April 25 amid risk aversion ahead of election results on May 16.
-
2013: Few bitter pills, booster injections for pharma sector
Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.
-
Morgan Stanley downgrades Cipla, a day after Macquarie's upgrade
The bank said the drugmaker's move to build a marketing and sales front-end operation in the United States and Europe will yield results only in the longer term.
-
Cipla shares soar after 62% jump in Q2 net
Shares in drug maker Cipla traded at the top of the 50-share Nifty benchmark on Tuesday on the back of strong quarterly earnings. Cipla beat estimates with a 62 per cent annual jump in net profit for the second quarter ending September 2012. Results came in after markets closed on Monday.
-
Cipla Q3 Profit Dips 2.6% To Rs 729 Crore
Cipla on Tuesday reported a 2.6 per cent decline in its consolidated profit after tax to Rs 729 crore for the third quarter ended on December 31, 2021
-
Cipla Records Rs 712 Crore Net Profit In September Quarter
The company's EBITDA or earnings before interest, tax, depreciation and amortisation also went up by 4.2 per cent to Rs 1,226.2 crore
-
Nifty Seen Opening Higher; Axis Bank, Kotak Bank, Cipla In Focus
Foreign institutional investors sold shares worth Rs 2,459 crore on Monday while domestic institutional investors bought shares worth Rs 2,390 crore.
-
Cipla Extends Gains For Second Straight Day On Strong June Quarter Earnings
On Friday, the company had reported a net profit of Rs 577.91 crore in the quarter ended June 30, marking a jump of 20.85 per cent compared to the corresponding period a year ago.
-
Cipla Hits Record High After Strong June Quarter Earnings
Cipla Share Price: By 11:22 am, 6.88 lakh Cipla shares had changed hands on the BSE, as against an average of 3.49 lakh over the past two weeks.
-
Cipla June Quarter Profit Jumps 21%
Cipla's revenue from the pharmaceuticals segment rose 7.73 per cent to Rs 4,266.09 crore.
-
Cipla Profit Rises 6% To Rs 478 Crore In June Quarter
Cipla's revenue from its pharmaceuticals business increased 1.22 per cent to Rs 3,959.93 crore in the quarter ended June 30.
-
Cipla Q2 Net Profit Falls 11%, Misses Street Estimates
The upcoming challenges include capacity balancing in certain categories at plants and sanctions, Cipla said in a post-earnings presentation.
-
Cipla Q2 Profit Soars 19 per Cent To Rs 423 Crore On Higher Domestic Sales
Cipla posted its second straight rise in quarterly profit, slightly above analysts' estimate, boosted by strong domestic sales.
-
Cipla Shares Jump Over 7% Post Q2 Results
Drug major Cipla yesterday reported a 34.74 per cent slide in consolidated net profit to Rs 354.34 crore for the second quarter ended September 2016, mainly on account of increase in expenditure.
-
Cipla Slips as CLSA Downgrades Stock
CLSA said that the business transformation could take longer than expected and results could take time to deliver.
-
Sensex Turns Flat After Strong Start; Nifty Holds 6,650
Indian stocks have witnessed low volumes and high volatility over the last 7-8 sessions. The Sensex has shed over 500 points since April 25 amid risk aversion ahead of election results on May 16.
-
2013: Few bitter pills, booster injections for pharma sector
Domestic firms coming under increased scrutiny of global regulators, resulting in Ranbaxy paying a record $500-million fine, and drugs becoming cheaper in India thanks to a new pricing policy marked a roller-coaster year 2013 for the pharma industry.
-
Morgan Stanley downgrades Cipla, a day after Macquarie's upgrade
The bank said the drugmaker's move to build a marketing and sales front-end operation in the United States and Europe will yield results only in the longer term.
-
Cipla shares soar after 62% jump in Q2 net
Shares in drug maker Cipla traded at the top of the 50-share Nifty benchmark on Tuesday on the back of strong quarterly earnings. Cipla beat estimates with a 62 per cent annual jump in net profit for the second quarter ending September 2012. Results came in after markets closed on Monday.
